Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2019
Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell TransplantationThomas P Slavin, Jennifer Berano Teh, Jeffrey N Weitzel, et al.
Leukemia & Lymphoma|August 6, 2025
Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphomaAnnie Xiao, Lu Chen, Stacy Pak, et al.
Frontiers in Immunology|October 16, 2024
Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapyColton Ladbury, Claire Hao, William Tyler Watkins, et al.
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
American Journal of Hematology|May 27, 2024
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemiaTamer Othman, Shanpeng Li, Jianying Zhang, et al.
Blood Advances|December 10, 2019
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agentsIbrahim Aldoss, Sanjeet Dadwal, Jianying Zhang, et al.
Blood Advances|September 28, 2021
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label studyHaris Ali, Ni-Chun Tsai, Timothy Synold, et al.
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Haematologica|July 20, 2023
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphomaJames Godfrey, Matthew Mei, Lu Chen, et al.
Pageof 8